Compare Stocks: SRPT, CTMX, EDIT, and PTGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.71	$3.49	$1.90 ▼ $8.21	$808.41M	2.14	3.05 million shs	2.30 million shs
EDIT Editas Medicine	$3.23	$3.03	$1.66 ▼ $4.54	$496.06M	2.09	2.55 million shs	1.39 million shs
PTGX Protagonist Therapeutics	$145.72	$141.67	$54.50 ▼ $160.81	$9.43B	1.8	485,569 shs	501,296 shs
SRPT Sarepta Therapeutics	$22.50	$18.37	$14.68 ▼ $25.32	$2.38B	0.27	2.89 million shs	2.96 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	+10.42%	+7.23%	+24.50%	+62.72%
EDIT Editas Medicine	0.00%	+5.56%	+12.15%	+21.89%	+17.03%
PTGX Protagonist Therapeutics	0.00%	-1.37%	-0.10%	+37.64%	+140.74%
SRPT Sarepta Therapeutics	0.00%	+6.99%	+34.09%	+41.60%	+20.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.71	$3.49	$1.90 ▼ $8.21	$808.41M	2.14	3.05 million shs	2.30 million shs
EDIT Editas Medicine	$3.23	$3.03	$1.66 ▼ $4.54	$496.06M	2.09	2.55 million shs	1.39 million shs
PTGX Protagonist Therapeutics	$145.72	$141.67	$54.50 ▼ $160.81	$9.43B	1.8	485,569 shs	501,296 shs
SRPT Sarepta Therapeutics	$22.50	$18.37	$14.68 ▼ $25.32	$2.38B	0.27	2.89 million shs	2.96 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	+10.42%	+7.23%	+24.50%	+62.72%
EDIT Editas Medicine	0.00%	+5.56%	+12.15%	+21.89%	+17.03%
PTGX Protagonist Therapeutics	0.00%	-1.37%	-0.10%	+37.64%	+140.74%
SRPT Sarepta Therapeutics	0.00%	+6.99%	+34.09%	+41.60%	+20.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	220.75% Upside
EDIT Editas Medicine	2.60	Moderate Buy	$6.00	85.76% Upside
PTGX Protagonist Therapeutics	2.89	Moderate Buy	$147.13	0.97% Upside
SRPT Sarepta Therapeutics	2.20	Hold	$25.06	11.37% Upside

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	PTGX Protagonist Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$153.00 ➝ $180.00
9/1/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$178.00 ➝ $190.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$175.00 ➝ $182.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	PTGX Protagonist Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$167.00 ➝ $170.00
8/19/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
8/17/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$112.00 ➝ $178.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$76.20M	10.61	N/A	N/A	$0.58 per share	6.40
EDIT Editas Medicine	$40.52M	12.24	N/A	N/A	$0.28 per share	11.54
PTGX Protagonist Therapeutics	$46.02M	204.90	N/A	N/A	$9.83 per share	14.82
SRPT Sarepta Therapeutics	$2.20B	1.08	N/A	N/A	$10.89 per share	2.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	141.48	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	12.36	0.32	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)

Latest SRPT, CTMX, EDIT, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
EDIT Editas Medicine	N/A	3.19	3.19
PTGX Protagonist Therapeutics	N/A	21.71	21.71
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EDIT Editas Medicine	71.90%
PTGX Protagonist Therapeutics	98.63%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
EDIT Editas Medicine	3.10%
PTGX Protagonist Therapeutics	5.19%
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	217.90 million	209.62 million	Optionable
EDIT Editas Medicine	230	153.58 million	148.82 million	Optionable
PTGX Protagonist Therapeutics	120	64.71 million	61.35 million	Optionable
SRPT Sarepta Therapeutics	1,372	105.63 million	98.34 million	Optionable

SRPT, CTMX, EDIT, and PTGX Headlines

Recent News About These Companies

Jupiter Topco LLC Takes Position in Sarepta Therapeutics, Inc. $SRPT

September 7 at 5:03 AM | marketbeat.com

The Manufacturers Life Insurance Company Makes New $927,000 Investment in Sarepta Therapeutics, Inc. $SRPT

September 6 at 4:24 AM | marketbeat.com

Sarepta Therapeutics, Inc. $SRPT Shares Sold by AXQ Capital LP

September 6 at 3:12 AM | marketbeat.com

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

September 4, 2026 | prnewswire.com

Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?

September 4, 2026 | zacks.com

Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?

September 4, 2026 | finance.yahoo.com

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

September 3, 2026 | theglobeandmail.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 6.6% - Should You Buy?

September 2, 2026 | marketbeat.com

Empowered Funds LLC Acquires Shares of 190,586 Sarepta Therapeutics, Inc. $SRPT

September 2, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

September 2, 2026 | marketbeat.com

70,233 Shares in Sarepta Therapeutics, Inc. $SRPT Purchased by Hsbc Holdings PLC

September 1, 2026 | marketbeat.com

Canada Pension Plan Investment Board Buys Shares of 70,800 Sarepta Therapeutics, Inc. $SRPT

September 1, 2026 | marketbeat.com

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

August 31, 2026 | businesswire.com

Legal & General Group Plc Takes Position in Sarepta Therapeutics, Inc. $SRPT

August 31, 2026 | marketbeat.com

Man Group plc Takes $7.16 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 30, 2026 | marketbeat.com

Freestone Grove Partners LP Acquires Shares of 76,629 Sarepta Therapeutics, Inc. $SRPT

August 30, 2026 | marketbeat.com

Jefferies Financial Group Inc. Takes $3.42 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 29, 2026 | marketbeat.com

Deutsche Bank AG Takes $2.04 Million Position in Sarepta Therapeutics, Inc. $SRPT

August 29, 2026 | marketbeat.com

Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution

August 28, 2026 | seekingalpha.com

OMERS ADMINISTRATION Corp Takes $864,000 Position in Sarepta Therapeutics, Inc. $SRPT

August 28, 2026 | marketbeat.com

SRPT Poised for Biggest Rally in 5 Months as Late-2026 Clinical Data Sparks Retail Investors’ ‘Monumental Comeback’

August 27, 2026 | profitconfidential.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SRPT, CTMX, EDIT, and PTGX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$3.71 0.00 (0.00%)

Closing price 09/4/2026 04:00 PM Eastern

Extended Trading

$3.70 -0.02 (-0.40%)

As of 06:50 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$3.23 0.00 (0.00%)

Closing price 09/4/2026 04:00 PM Eastern

Extended Trading

$3.23 0.00 (-0.12%)

As of 05:56 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$145.72 0.00 (0.00%)

Closing price 09/4/2026 04:00 PM Eastern

Extended Trading

$145.74 +0.02 (+0.01%)

As of 06:03 AM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Sarepta Therapeutics NASDAQ:SRPT

$22.50 0.00 (0.00%)

Closing price 09/4/2026 04:00 PM Eastern

Extended Trading

$20.16 -2.34 (-10.38%)

As of 06:56 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, CTMX, EDIT, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, CTMX, EDIT, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRPT, CTMX, EDIT, and PTGX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Editas Medicine NASDAQ:EDIT

Protagonist Therapeutics NASDAQ:PTGX

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, CTMX, EDIT, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, CTMX, EDIT, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRPT, CTMX, EDIT, and PTGX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Editas Medicine NASDAQ:EDIT

Protagonist Therapeutics NASDAQ:PTGX

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools